Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Debt to Equity (2016 - 2022)

Historic Debt to Equity for Lexaria Bioscience (LEXX) over the last 10 years, with Q2 2022 value amounting to $0.0.

  • Lexaria Bioscience's Debt to Equity rose 2130.7% to $0.0 in Q2 2022 from the same period last year, while for May 2022 it was $0.0, marking a year-over-year increase of 2130.7%. This contributed to the annual value of $0.0 for FY2021, which is 9831.49% down from last year.
  • Per Lexaria Bioscience's latest filing, its Debt to Equity stood at $0.0 for Q2 2022, which was up 2130.7% from $0.0 recorded in Q1 2022.
  • Lexaria Bioscience's 5-year Debt to Equity high stood at $0.06 for Q4 2020, and its period low was $0.0 during Q3 2021.
  • Moreover, its 5-year median value for Debt to Equity was $0.0 (2018), whereas its average is $0.01.
  • Its Debt to Equity has fluctuated over the past 5 years, first crashed by 9950.65% in 2018, then skyrocketed by 202381.06% in 2021.
  • Over the past 5 years, Lexaria Bioscience's Debt to Equity (Quarter) stood at $0.01 in 2018, then skyrocketed by 124.29% to $0.01 in 2019, then skyrocketed by 355.67% to $0.06 in 2020, then crashed by 98.95% to $0.0 in 2021, then soared by 30.14% to $0.0 in 2022.
  • Its last three reported values are $0.0 in Q2 2022, $0.0 for Q1 2022, and $0.0 during Q4 2021.